Metabolic syndrome and its factors are associated with noncalcified coronary burden in psoriasis: An observational cohort study

Psoriasis is associated with a heightened risk of cardiovascular disease and higher prevalence of metabolic syndrome. Investigate the effect of metabolic syndrome and its factors on early coronary artery disease assessed as noncalcified coronary burden by coronary computed tomography angiography in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Academy of Dermatology 2021-05, Vol.84 (5), p.1329-1338
Hauptverfasser: Teklu, Meron, Zhou, Wunan, Kapoor, Promita, Patel, Nidhi, Dey, Amit K., Sorokin, Alexander V., Manyak, Grigory A., Teague, Heather L., Erb-Alvarez, Julie A., Sajja, Aparna, Abdelrahman, Khaled M., Reddy, Aarthi S., Uceda, Domingo E., Lateef, Sundus S., Shanbhag, Sujata M., Scott, Colin, Prakash, Nina, Svirydava, Maryia, Parel, Philip, Rodante, Justin A., Keel, Andrew, Siegel, Evan L., Chen, Marcus Y., Bluemke, David A., Playford, Martin P., Gelfand, Joel M., Mehta, Nehal N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Psoriasis is associated with a heightened risk of cardiovascular disease and higher prevalence of metabolic syndrome. Investigate the effect of metabolic syndrome and its factors on early coronary artery disease assessed as noncalcified coronary burden by coronary computed tomography angiography in psoriasis. This cross-sectional study consisted of 260 participants with psoriasis and coronary computed tomography angiography characterization. Metabolic syndrome was defined according to the harmonized International Diabetes Federation criteria. Of the 260 participants, 80 had metabolic syndrome (31%). The metabolic syndrome group had a higher burden of cardiometabolic disease, systemic inflammation, noncalcified coronary burden, and high-risk coronary plaque. After adjusting for Framingham risk score, lipid-lowering therapy, and biologic use, metabolic syndrome (β = .31; P 
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2020.12.044